PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Non-randomized, open label, multicentric translational research study in women with untreated
invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
The aim of PAMELA is to test the hypothesis that PAM50 HER2-enriched (HER2-E) subtype better
predicts response to neoadjuvant dual anti-HER2 blockade, with or without endocrine therapy,
compared to traditional clinical HER2 classification. Furthermore, we posit that
characterization of gene expression patterns may identify profiles of those who may be safely
spared chemotherapy.